Trends of Exposure to Acrylamide as Measured by Urinary Biomarkers Levels within the HBM4EU Biomonitoring Aligned Studies (2000–2021)

Michael Poteser*, Federica Laguzzi, Thomas Schettgen, Nina Vogel, Till Weber, Aline Murawski, Phillipp Schmidt, Maria Rüther, Marike Kolossa-Gehring, Sónia Namorado, An Van Nieuwenhuyse, Brice Appenzeller, Edda Dufthaksdóttir, Kristín Olafsdóttir, Line Småstuen Haug, Cathrine Thomsen, Fabio Barbone, Valentina Rosolen, Loïc Rambaud, Margaux RiouThomas Göen, Stefanie Nübler, Moritz Schäfer, Karin H.A. Zarrabi, Liese Gilles, Laura Rodriguez Martin, Greet Schoeters, Ovnair Sepai, Eva Govarts, Hanns Moshammer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Acrylamide, a substance potentially carcinogenic in humans, represents a very prevalent contaminant in food and is also contained in tobacco smoke. Occupational exposure to higher concentrations of acrylamide was shown to induce neurotoxicity in humans. To minimize related risks for public health, it is vital to obtain data on the actual level of exposure in differently affected segments of the population. To achieve this aim, acrylamide has been added to the list of substances of concern to be investigated in the HBM4EU project, a European initiative to obtain biomonitoring data for a number of pollutants highly relevant for public health. This report summarizes the results obtained for acrylamide, with a focus on time-trends and recent exposure levels, obtained by HBM4EU as well as by associated studies in a total of seven European countries. Mean biomarker levels were compared by sampling year and time-trends were analyzed using linear regression models and an adequate statistical test. An increasing trend of acrylamide biomarker concentrations was found in children for the years 2014–2017, while in adults an overall increase in exposure was found to be not significant for the time period of observation (2000–2021). For smokers, represented by two studies and sampling for, over a total three years, no clear tendency was observed. In conclusion, samples from European countries indicate that average acrylamide exposure still exceeds suggested benchmark levels and may be of specific concern in children. More research is required to confirm trends of declining values observed in most recent years.

Original languageEnglish
Article number443
JournalToxics
Volume10
Issue number8
DOIs
Publication statusPublished - Aug 2022
Externally publishedYes

Bibliographical note

Funding Information:
This work received external funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 733032 and received co-funding from the author’s organizations. The Norwegian Institute of Public Health (NIPH) contributed to the funding of the Norwegian Environmental Biobank (NEB). The laboratory measurements were partly funded by the Research Council of Norway through research projects (275903 and 268465).

Funding Information:
The authors acknowledge all the participating and expert laboratories involved, including the HBM4EU QA/QC program, the Management and Advisory Boards of HBM4EU, and the funding received from the European Union’s Horizon 2020 research and innovation program (grant agreement No 733032).

Publisher Copyright:
© 2022 by the authors.

Keywords

  • HBM4EU
  • acrylamide
  • exposure level
  • glycidamide
  • time-trend

Fingerprint

Dive into the research topics of 'Trends of Exposure to Acrylamide as Measured by Urinary Biomarkers Levels within the HBM4EU Biomonitoring Aligned Studies (2000–2021)'. Together they form a unique fingerprint.

Cite this